Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options

Ann Med. 2024 Dec;56(1):2329132. doi: 10.1080/07853890.2024.2329132. Epub 2024 Apr 12.ABSTRACTMyeloid neoplasms post cytotoxic therapy (MN-pCT) are a category includes AML, MDS, and MDS/MPN arising in patients exposed to cytotoxic (DNA-damaging) therapy for an unrelated condition in 2022 version World Health Organization (WHO) classification. With improved survival of patients with tumors, the incidence of MN-pCT after chemotherapy and/or radiation therapy among patients with tumors has gradually risen. However, the outcome of MN-pCT is poorer than that of primary myeloid neoplasms. This review summarizes the current understanding based on existing research, as a foundation for further research on MN-pCT.PMID:38608646 | DOI:10.1080/07853890.2024.2329132
Source: Annals of Medicine - Category: Internal Medicine Authors: Source Type: research